Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres

Bone Marrow Transplantation volume 54, pages 1434–1442 (2019)Cite this article

Subjects

Abstract

While performance since the introduction of the JACIE quality management system has been shown to be improved for allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007–2013) aims at comparing the adjusted 1 and 3-yr survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT performed by centres: exclusively autologous vs both autologous & allogeneic). We showed a relatively homogeneous performance between Belgian centres before national completeness of JACIE implementation. The 3 centre-related factors had a significant impact on the 1-yr survival, while activity volume and type of HSCT impacted the 3-yr survival of autologous-HSCT patients in univariable analyses. Only activity volume (impact on 1-yr survival only) and type of HSCT (impact on 1 and 3-yr survivals) remained significant in multivariable analysis. This is explained by the strong relationship between these 3 variables. An extended transplantation experience, i.e., performing both auto & allo-HSCT, appears to be a newly informative quality indicator potentially conveying a multitude of underlying complex factors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.

    Article  CAS  Google Scholar 

  2. Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Bin Rias I, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12:217–26.

    Article  Google Scholar 

  3. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:17008.

    Article  Google Scholar 

  4. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.

    Article  CAS  Google Scholar 

  5. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–7.

    Article  CAS  Google Scholar 

  6. Saba N, Abraham R, Keating A. Overview of autologous stem cell transplantation. Crit Rev Oncol Hematol. 2000;36:27–48.

    Article  CAS  Google Scholar 

  7. Ljungman P, Bregni M, Brune M, de Witte T, Dini G, Einsele H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219–34.

    Article  CAS  Google Scholar 

  8. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9.

    Article  Google Scholar 

  9. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–56.

    Article  CAS  Google Scholar 

  10. Peters WP, Dansey R, Baynes RD. Autologous bone marrow and stem cell transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Holland-Frei Cancer Medicine. B.C. Decker; 2003.

  11. Champlin R. Hematopoietic cellular transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Holland-Frei Cancer Medicine. B.C. Decker; 2003.

  12. Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15:18–25.

    Article  CAS  Google Scholar 

  13. Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327–32.

    Article  CAS  Google Scholar 

  14. Blume KG, Thomas ED. A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:1–12.

    Article  CAS  Google Scholar 

  15. Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52:1367–71.

    Article  CAS  Google Scholar 

  16. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29:1980–6.

    Article  Google Scholar 

  17. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, et al. Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation. Haematologica. 2014;99:908–15.

    Article  Google Scholar 

  18. Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, et al. CLL subcommittee, Chronic Malignancies Working Party. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2017;178:521–33.

    Article  Google Scholar 

  19. Royal Decree amending article 20, § 1, a), of the annex to the Royal Decree of 14 September 1984 establishing the nomenclature of health care benefits, on compulsory insurance for health care and allowances. Belgisch Staatsblad / Moniteur Belge; 2012-12-06/09.

  20. Haematological malignancies in Belgium, Belgian Cancer Registry, Brussels 2015.

  21. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

    Article  CAS  Google Scholar 

  22. Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

    Article  Google Scholar 

  23. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120:1398–408.

    Article  CAS  Google Scholar 

  24. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

    CAS  PubMed  Google Scholar 

  25. Andersen PK, Klein JP, Rosthøj S. Generalised linear models for correlated pseudo-observations, with applications to multi-state models. Biometrika. 2003;90:15–27.

    Article  Google Scholar 

  26. Logan BR. Review of multistate models in hematopoietic cell transplantation studies. Biol Blood Marrow Transplant. 2013;19:S84–S87.

    Article  CAS  Google Scholar 

  27. Hurvich CM, Tasi C-L. Regression and time series model selection in small samples. Biometrika. 1989;ume 76(Issue 2):297–330.

    Article  Google Scholar 

  28. Logan BR, Nelson GO, Klein JP. Analyzing center specific outcomes in hematopoietic cell transplantation. Lifetime Data Anal. 2008;14:389–404.

    Article  Google Scholar 

  29. Anthias C, Ethell ME, Potter MN, Madrigal A, Shaw BE. The impact of improved JACIE standards on the care of related BM and PBSC donors. Bone Marrow Transplant. 2015;50:244–7.

    Article  CAS  Google Scholar 

  30. Anthias C, O’Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, et al. European Group for Blood and Marrow Transplantation Centers with FACT-JACIE accreditation have significantly better compliance with related donor care standards. Biol Blood Marrow Transplant. 2016;22:514–9.

    Article  Google Scholar 

  31. Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP); EBMT Paediatric Working Party (PWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); EBMT (JACIE). Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742–55.

    Article  Google Scholar 

  32. Horowitz MM, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood. 1992;79:2771–4.

    CAS  PubMed  Google Scholar 

  33. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant. 1993;12:371–80.

    CAS  PubMed  Google Scholar 

  34. Matsuo K, Hamajima N, Morishima Y, Harada M. Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for hematopoietic cell transplantation. Bone Marrow Transplant. 2000;26:1061–7.

    Article  CAS  Google Scholar 

  35. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000;355:1393–8.

    Article  CAS  Google Scholar 

  36. Loberiza FR Jr., Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003;31:417–21.

    Article  Google Scholar 

  37. LeMaistre CF, Loberiza FR Jr. What is quality in a transplant program? Biol Blood Marrow Transplant. 2005;11:241–6.

    Article  Google Scholar 

  38. Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, et al. Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) and the European Leukemia Net (ELN). Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine. 2015;2:2101–9.

Download references

Author information

Author notes

  1. These authors contributed equally: Hélène A. Poirel, Marijke Vanspauwen

Authors and Affiliations

  1. Belgian Cancer Registry, Brussels, Belgium

    Hélène A. Poirel, Marijke Vanspauwen, Gilles Macq, Anke De Geyndt & Evelien Vaes

  2. UZ Gasthuisberg Leuven, Leuven, Belgium

    Johan Maertens

  3. CHU de Liège, Liège, Belgium

    Evelyne Willems & Yves Beguin

  4. AZ Sint Jan Brugge-Oostende, Brugge, Belgium

    Dominik Selleslag

  5. UCL St-Luc, Brussels, Belgium

    Xavier Poiré

  6. Jessa Ziekenhuis, Hasselt, Belgium

    Koen Theunissen

  7. CHU UCL Namur (Godinne site), Yvoir, Belgium

    Carlos Graux

  8. UZ Gent, Gent, Belgium

    Tessa Kerre

  9. Belgian Hematological Society—Transplant Committee, Brussels, Belgium

    Tessa Kerre & Yves Beguin

  10. ZNA Antwerpen, Antwerpen, Belgium

    Pierre Zachée

  11. Co-chair of the Belgian Transplant Registry, Brussels, Belgium

    Pierre Zachée & Yves Beguin

  12. Institut Jules Bordet, Brussels, Belgium

    Nathalie Meuleman

  13. UZ Brussel, Brussels, Belgium

    Ann De Becker & Ivan Van Riet

  14. Antwerp University Hospital, Edegem, Belgium

    Anke Verlinden

  15. Hopital de Jolimont, La Louvière, Belgium

    Florence Van Obbergh

  16. GZA Sint-Augustinus, Wilrijk, Belgium

    Christine Schuermans

  17. Erasmus Brussel, Brussels, Belgium

    Virginie De Wilde

  18. CHR Citadelle, Liège, Belgium

    Aurélie Jaspers & Yves Beguin

  19. Grand Hôpital de Charleroi, Charleroi, Belgium

    Delphine Pranger

  20. AZ Delta, Roeselare, Belgium

    Dries Deeren

  21. Chair of the Belgian Hematological Society – JACIE Committee, Brussels, Belgium

    Ivan Van Riet

Authors
  1. Hélène A. Poirel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marijke Vanspauwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilles Macq
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anke De Geyndt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Evelyne Willems
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dominik Selleslag
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xavier Poiré
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koen Theunissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carlos Graux
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tessa Kerre
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Pierre Zachée
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nathalie Meuleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ann De Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Anke Verlinden
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Florence Van Obbergh
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Christine Schuermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Virginie De Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Aurélie Jaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Delphine Pranger
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Dries Deeren
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Ivan Van Riet
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Evelien Vaes
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Yves Beguin
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee

Corresponding author

Correspondence to Hélène A. Poirel.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poirel, H.A., Vanspauwen, M., Macq, G. et al. Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. Bone Marrow Transplant 54, 1434–1442 (2019). https://doi.org/10.1038/s41409-019-0458-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0458-8

This article is cited by

Search

Advanced search

Quick links